Insider Trading Alert - YHOO, MFRM And SYNT Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, June 3, 2014, 107 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $420.42 to $5,791,625.60.

Highlighted Stocks Traded by Insiders:

Yahoo (YHOO) - FREE Research Report

Kothari Aman S, who is SVP, Global Controller & CAO at Yahoo, sold 195 shares at $34.92 on June 3, 2014. Following this transaction, the SVP, Global Controller & CAO owned 87,968 shares meaning that the stake was reduced by 0.22% with the 195-share transaction.

The shares most recently traded at $34.69, down $0.23, or 0.66% since the insider transaction. Historical insider transactions for Yahoo go as follows:

  • 4-Week # shares sold: 226
  • 12-Week # shares sold: 616
  • 24-Week # shares sold: 21,435

The average volume for Yahoo has been 22.9 million shares per day over the past 30 days. Yahoo has a market cap of $35.1 billion and is part of the technology sector and internet industry. Shares are down 14.32% year-to-date as of the close of trading on Tuesday.

Yahoo! Inc. operates as a technology company worldwide. The company has a P/E ratio of 29.1. Currently, there are 19 analysts who rate Yahoo a buy, no analysts rate it a sell, and 9 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on YHOO - FREE

TheStreet Quant Ratings rates Yahoo as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, expanding profit margins and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Yahoo Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Mattress Firm (MFRM) - FREE Research Report

Fendrich Stephen G., who is Chief Strategy Officer at Mattress Firm, sold 2,500 shares at $45.06 on June 3, 2014. Following this transaction, the Chief Strategy Officer owned 208,735 shares meaning that the stake was reduced by 1.18% with the 2,500-share transaction.

The shares most recently traded at $45.45, up $0.39, or 0.85% since the insider transaction. Historical insider transactions for Mattress Firm go as follows:

  • 4-Week # shares sold: 11,075
  • 12-Week # shares sold: 30,741
  • 24-Week # shares sold: 50,407

The average volume for Mattress Firm has been 219,000 shares per day over the past 30 days. Mattress Firm has a market cap of $1.6 billion and is part of the services sector and specialty retail industry. Shares are up 5.69% year-to-date as of the close of trading on Tuesday.

Mattress Firm Holding Corp., through its subsidiaries, operates as a specialty retailer of mattresses, and related products and accessories in the United States. The company has a P/E ratio of 29.6. Currently, there are 7 analysts who rate Mattress Firm a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MFRM - FREE

TheStreet Quant Ratings rates Mattress Firm as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, growth in earnings per share and good cash flow from operations. However, as a counter to these strengths, we find that the company has favored debt over equity in the management of its balance sheet. Get the full Mattress Firm Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Syntel (SYNT) - FREE Research Report

Moore Daniel M, who is Chief Administrative Officer at Syntel, sold 625 shares at $78.66 on June 3, 2014. Following this transaction, the Chief Administrative Officer owned 7,051 shares meaning that the stake was reduced by 8.14% with the 625-share transaction.

The shares most recently traded at $78.86, up $0.20, or 0.26% since the insider transaction. Historical insider transactions for Syntel go as follows:

  • 4-Week # shares sold: 29,475
  • 12-Week # shares sold: 29,475
  • 24-Week # shares sold: 32,850

The average volume for Syntel has been 110,700 shares per day over the past 30 days. Syntel has a market cap of $3.3 billion and is part of the technology sector and computer software & services industry. Shares are down 12.73% year-to-date as of the close of trading on Tuesday.

Syntel, Inc. provides information technology (IT) and knowledge process outsourcing (KPO) services worldwide. The company operates in four segments: Applications Outsourcing, KPO, e-Business, and TeamSourcing. The stock currently has a dividend yield of 0.36%. The company has a P/E ratio of 14.5. Currently, there are 3 analysts who rate Syntel a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SYNT - FREE

TheStreet Quant Ratings rates Syntel as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, expanding profit margins and good cash flow from operations. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Syntel Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: There Are Some Big Changes Coming to the PGA Championships in 2019

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

Video: One-on-One With Pluralsight's CEO Following Its Successful IPO

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Listen: Here's What You Need To Know About ETFs Today (Hint: They're on Fire!)

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing

Cramer and His Team Stick to Their Disciplines -- Even When It's Disappointing